Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific (NYSE: TMO).
Athena Diagnostics will continue to operate under its own name as an independent business within Quest Diagnostics. Its clinical laboratory in Worcester, Massachusetts, is now the center of excellence in neurology diagnostics for Quest Diagnostics.
"With this acquisition, Quest Diagnostics has clearly established the leading position in the neurology diagnostics market," said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer of Quest Diagnostics. "Patients and healthcare providers will realize significant benefits from the transaction, including greater access, convenience and breadth of diagnostic services expertise than either company could offer alone."
New diagnostic approach may help physicians more efficiently screen for dementia